Co-Inhibition of BCL-W and BCL2 Restores Antiestrogen Sensitivity through BECN1 and Promotes an Autophagy-Associated Necrosis

Anatasha C. Crawford, Rebecca B. Riggins, Ayesha N. Shajahan et al. · 2010

Read Co-Inhibition of BCL-W and BCL2 Restores Antiestrogen Sensitivity through BECN1 and Promotes an Autophagy-Associated Necrosis by Anatasha C. Crawford, Rebecca B. Riggins, Ayesha N. Shajahan et al. (2010) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0008604.txt.

Description

Anatasha Crawford and co-authors study drug resistance in breast cancer in a 2010 PLOS ONE paper. BCL2 family members affect cell fate decisions in breast cancer. The role of BCL-W, also called BCL2L2, was unknown. Both BCL-W and BCL2 block apoptosis, the cell death program. Antiestrogen drugs such as fulvestrant treat hormone-sensitive breast cancers. The team test how these blockers affect response to that drug, using cell and tumor models.

Co-inhibition of BCL-W and BCL2 restores antiestrogen sensitivity. It does so through BECN1, a gene that drives autophagy. The treated cells die by an autophagy-associated necrosis. Blocking both survival proteins may rescue failing hormone therapy.

Catalog record

CREATORAnatasha C. Crawford, Rebecca B. Riggins, Ayesha N. Shajahan et al.
YEAR2010
COLLECTIONPAPERS
FORMATTXT
FILE SIZE45 KB
LICENSECreative Commons Attribution License
RIGHTSCC BY
SOURCEPLOS ONE

Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0008604

Browse the full library · About the Tower of Babel